Showing results (261-270 of 380) with videos related to
Sort By:
Pageof 38
Diabetes, Obesity & Metabolism|June 30, 2017
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.Diabetes, Obesity & Metabolism|February 3, 2015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)G B Bolli, M C Riddle, R M Bergenstal, et al.Diabetes Care|June 19, 2015
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)Philip D Home, Richard M Bergenstal, Geremia B Bolli, et al.Science Advances|June 19, 2026
A three-dimensional scanning trapped-ion probeTobias Sägesser, Shreyans Jain, Pavel Hrmo, et al.Nature|May 22, 2015
Spin-motion entanglement and state diagnosis with squeezed oscillator wavepacketsHsiang-Yu Lo, Daniel Kienzler, Ludwig de Clercq, et al.Diabetes Research (Edinburgh, Scotland)|November 1, 1984
The response of blood intermediary metabolite levels to 24 hours treatment with a blood glucose-controlled insulin infusion system in type 1 diabetesB Capaldo, P D Home, M Massi-Benedetti, et al.Diabetes, Obesity & Metabolism|December 7, 2018
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0David R Owens, Wolfgang Landgraf, Brian M Frier, et al.Diabetologia|September 1, 1982
The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas)R Nosadini, G A Noy, M Nattrass, et al.Diabetes, Obesity & Metabolism|September 2, 2022
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trialRory J McCrimmon, Philip Home, Alice Cheng, et al.Diabetes, Obesity & Metabolism|April 8, 2015
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extensionM C Riddle, H Yki-Järvinen, G B Bolli, et al.Pageof 38